cardiovascular benefit and diabetes

Created by:

2 Jul 2016 - General

Linagliptin appear as another agent that has cardiovascular benefit after the SGLT2 inhibitor (EMPAREG trial)

Linagliptin is a Dipeptidyl peptidase-4 (DPP-4) inhibitor that reduces plasma glucose levels the action of which is achieved by an increase in incretin levels, which is a metabolic hormone that in turn results in a reduction of circulating glucagon levels, increase in insulin secretion, delayed gastric emptying and slowing down of the rate of absorption of nutrients. Sodium/Glucose Co-transporter 2 (SGLT2) inhibitors reduce plasma glucose mainly by reducing the absorption of glucose from the re...
 (Total 112 words)